Research Studies Finder

For this study, we are studying the relationship between variations in the genes of the immune system called HLA and how they relate to:

1. The risk of developing nephrotic syndrome
2. The response to treatment of nephrotic syndrome and
3. The risk of recurrence of nephrotic syndrome following kidney transplantation.

1. Clinical diagnosis of nephrotic syndrome
2. Biopsy proven diagnosis of FSGS or MCD and,
3. History of living or deceased donor kidney transplantation

In this study, we are developing new magnetic resonance imaging (MRI) and ultrasound methods to determine if it is effective in diagnosing complication in kidney transplant patients. Participants in this study will involve patients that have had a kidney transplant and are scheduled for a kidney biopsy. The study will also involve a comparison group of healthy individuals that have no history of kidney conditions. Study procedures will include a review of medical history and medications, MRI scan and ultrasound of the abdomen and blood/ urine test.

The purpose of this study is to identify components of a physical activity intervention that are effective and meaningful to teenagers with chronic kidney disease (CKD).

Participants will be assigned to 1 of the 16 study groups and will be asked to wear a Fitbit. Participants will also be given a step count goal, answer questionnaires, and complete hand grip strength assessments.

Participants may also be asked to have one-on-one meetings with an exercise coach.

All visits may be completed remotely.

CKiD is an important research study looking at the health of children, teenagers, and young adults who have kidney problems. This research is being done to identify what factors help kidneys stay healthy, and also to see how kidney problems affect health and well-being. Teenagers and young adults 16-22 years old who have been diagnosed with chronic kidney disease (CKD) may be eligible to join the study. The CKiD study has enrolled approximately 1100 children and teenagers across North America since the study began in 2003. Our goal now is to enroll teenagers and young adults in the study. By doing this we can have a better idea of what happens to kidney function and overall health as someone with childhood chronic kidney disease grows up. This will help provide us with a more complete picture of CKD from childhood through adulthood.

The purpose of this NIH-funded placebo-controlled clinical trial is to determine how well ferric citrate will lower FGF23, correct anemia and iron levels in the blood, and maintain normal levels of phosphate in children with CKD. Chronic Kidney Disease (CKD) is a condition in which the kidney function is decreased. Fibroblast Growth Factor 23 (FGF23) is a hormone that regulates blood phosphate levels. High FGF23 levels are linked with worsening of kidney, bone & heart health. Ferric Citrate is an oral medication that decreases the absorption of dietary phosphate by the gut, lowers FGF23 levels and raises iron stores in the body. Ferric Citrate is approved in adults with CKD but has not yet been studied in children.

For more information visit www.fit4kidstudy.com

This is a two-by-two factorial, response-adaptive multi-center randomized controlled clinical trial that tests whether pediatric patients with severe PARDS randomized to supine versus prone positioning and to CMV versus HFOV exhibit more VFD over a 28-day period.

This pilot study is investigating the feasibility of a prospective biomarker study in the CICU by measuring enrollment of subjects, as well as the looking at outcomes. The goal of this study is to risk stratify neonates with congenital heart disease requiring neonatal cardiopulmonary bypass for poor outcomes in order to appropriately tailor medical care and for possible future trials.

The primary objective of this study is to collect biospecimens to conduct protein biomarker studies in patients with heart failure requiring advanced therapies such as OHT and VAD. A dedicated heart failure biospecimen repository will allow the Cardiac Center to be at the forefront of molecular sub-phenotyping to improve mechanistic understanding, clinical care, and trial design.

The study aims to determine the reasons why parents decline consent in PICU research by formally collecting these responses, grouping them into categories, and analyzing the data. The study aims to assess this of all parents of PICU children who decline prospective consent (in person or phone, with or without interpreter), without age restriction. About 500 sets of responses will be included in the analysis. This sample will also provide > 90% power to determine whether responses differ according to specific demographic information by 33%.

The study goal is to risk stratify pediatric (Acute Respiratory Distress Syndrome) ARDS patients and to identify sub-phenotypes with shared biology in order to appropriately target therapies in future trials. Specifically, the study aims to: Aim 1: Validate and refine PARDSEVERE, a published protein biomarker-based pediatric ARDS risk stratification tool Aim 2: Stratify pediatric ARDS into sub-phenotypes using a known 100-gene expression-based classifier to group subjects according to shared underlying biology Aim 3: Identify de novo sub-phenotypes in pediatric ARDS using biomarkers and whole genome transcriptomics of peripheral blood